TUCSON, Ariz. (KOLD News 13) - Today, the U.S. Food and Drug Adminstration announced the information for two new medications that recently underwent clinical trials.
The first is called Lupkynis (loop kye’ nis) and is used to treat patients with active lupus [nephritis], an inflammation of the kidneys that is caused by a chronic auto-immune disease.
According to the FDA, patients who received the drug for one year acheived major reduction in kidney inflammation.
The drug was taken by mouth twice daily in combination with two others.
Lupkynis is said to work similarily for men and women, and its most common side effects include kidney toxicity, high blood pressure, diarrhea, headache, anemia, cough and urinary tract infection.
The second drug known as Verquvo (ver kyu voh) will be used to reduce the risk of death and hospitalization in patients with long-lasting chronic heart failure, a condition where the heart is not pumping as well as it should be.
The drug, which is taken by mouth once daily, is not to be used by pregnant women.
Some of the common side effects include low blood pressure and low red blood cell count.
Verquvo will be used to treat patients having chronic health symptoms who have had a recent hospitalization, and those who need to receive intra-venous medicines.